Literature DB >> 35791431

Optimizing the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach.

Bhagyashri Chaudhari1, Harun Patel2, Snehal Thakar1, Iqrar Ahmad2, Deepali Bansode1.   

Abstract

Sunitinib is a potent anti-cancer scaffold that acts as a VEGFR-2 inhibitor. Although the scaffold exhibits potent anti-cancer activity, it is cardiotoxic and also induces hypothyroidism. The current research aims to optimize the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach using the admetSAR server. The server has optimized the physico-chemical properties of Sunitinib, which were contributing to the cardiotoxicity and thyro-toxicity. The library of the optimized compounds was further screened by the molecular docking studies and results were validated by the MD simulation and DFT analysis for VEGFR-2 inhibition. Compounds 163 and 432 exhibited the highest affinity to VEGFR-2 receptor with minimal cardiotoxicity and thyro-toxicity. These two compounds could be the starting point for the further discovery of angiogenic inhibitors. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-022-00125-1.
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.

Entities:  

Keywords:  Cardiotoxicity; Docking; Sunitinib; Thyro-toxicity; VEGFR-2

Year:  2022        PMID: 35791431      PMCID: PMC9250587          DOI: 10.1007/s40203-022-00125-1

Source DB:  PubMed          Journal:  In Silico Pharmacol        ISSN: 2193-9616


  34 in total

Review 1.  Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.

Authors:  Yujie Zhao; Alex A Adjei
Journal:  Oncologist       Date:  2015-05-22

2.  Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma.

Authors:  Petri Bono; Juhana Rautiola; Tapio Utriainen; Heikki Joensuu
Journal:  Acta Oncol       Date:  2011-01-05       Impact factor: 4.089

Review 3.  Role of tyrosine kinase inhibitors in cancer therapy.

Authors:  Amit Arora; Eric M Scholar
Journal:  J Pharmacol Exp Ther       Date:  2005-07-07       Impact factor: 4.030

4.  BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC).

Authors:  Harun M Patel; Matin Shaikh; Iqrar Ahmad; Deepak Lokwani; Sanjay J Surana
Journal:  J Biomol Struct Dyn       Date:  2020-04-23

Review 5.  Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?

Authors:  David Bruce; Peng H Tan
Journal:  Expert Opin Investig Drugs       Date:  2011-08-25       Impact factor: 6.206

6.  Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation.

Authors:  E P Hui; B B Y Ma; A D King; F Mo; S L Chan; M K M Kam; H H Loong; A T Ahuja; B C Y Zee; A T C Chan
Journal:  Ann Oncol       Date:  2011-02-11       Impact factor: 32.976

7.  Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.

Authors:  Jerome Guillemont; Christophe Meyer; Alain Poncelet; Xavier Bourdrez; Koen Andries
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

8.  5-Hydroxy-7-azaindolin-2-one, a novel hybrid of pyridinol and sunitinib: design, synthesis and cytotoxicity against cancer cells.

Authors:  Sajita Shah; Chaemin Lee; Hyukjae Choi; Jaya Gautam; Hyeonjin Jang; Geum Jin Kim; Yu-Jeong Lee; Chhabi Lal Chaudhary; Sang Won Park; Tae-Gyu Nam; Jung-Ae Kim; Byeong-Seon Jeong
Journal:  Org Biomol Chem       Date:  2016-05-05       Impact factor: 3.876

9.  Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: combined molecular docking and molecular dynamics approaches.

Authors:  Mathimaran Amala; Sundaraj Rajamanikandan; Dhamodharan Prabhu; Kanagarajan Surekha; Jeyaraman Jeyakanthan
Journal:  J Biomol Struct Dyn       Date:  2018-02-06

10.  Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.

Authors:  Anna Buda-Nowak; Jakub Kucharz; Paulina Dumnicka; Marek Kuzniewski; Roman Maria Herman; Aneta L Zygulska; Beata Kusnierz-Cabala
Journal:  Med Oncol       Date:  2017-03-25       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.